Physician profile
Edward Duffy
NPI 1205495884
$2,822.58
in general payments reported to CMS, 2019-2025
37 companies · $1,210 in 2025
The $1,210 reported for 2025 was more than what 85% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $87.20 · 2020: $205 · 2023: $220 · 2024: $1,100 · 2025: $1,210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,530.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,530.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $402.31 | 2020-2024 | Optune |
| Merck Sharp & Dohme LLC | $218.66 | 2024-2025 | Keytruda, Welireg, Lagevrio |
| Genentech USA, INC. | $163.33 | 2024-2025 | Venclexta, Polivy, Tecentriq |
| Eagle Pharmaceuticals, INC. | $154.99 | 2024 | |
| Lilly USA, LLC | $131.43 | 2024-2025 | Verzenio, Jaypirca, Retevmo |
| Abbvie INC. | $125.51 | 2024-2025 | |
| Blue Earth Diagnostics | $125.00 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $115.39 | 2024-2025 | Ninlaro, Iclusig, Alunbrig |
| Astrazeneca Pharmaceuticals LP | $114.34 | 2024-2025 | Calquence |
| Janssen Biotech, INC. | $109.50 | 2024-2025 | Erleada, Rybrevant, Balversa |
| Progenics Pharmaceuticals, INC. | $95.07 | 2023 | Pylarify |
| Boston Scientific Corporation | $87.20 | 2019 | |
| Daiichi Sankyo INC. | $83.22 | 2024-2025 | Enhertu, Injectafer |
| Aveo Pharmaceuticals, INC. | $78.67 | 2024-2025 | |
| Incyte Corporation | $72.62 | 2024-2025 | Jakafi, Niktimvo, Monjuvi |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $67.04 | 2025 | |
| Karyopharm Therapeutics INC. | $60.01 | 2024-2025 | Xpovio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.18 | 2024-2025 | Gilotrif |
| Puma Biotechnology, INC. | $51.89 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $49.81 | 2024 | |
| Servier Pharmaceuticals LLC | $48.98 | 2025 | |
| Pfizer INC. | $46.42 | 2024 | |
| Genmab U.S., INC. | $30.84 | 2024 | Tivdak |
| Eisai INC. | $30.71 | 2024 | |
| Novartis Pharmaceuticals Corporation | $30.47 | 2025 | |
| Pharmaessentia USA Corporation | $29.07 | 2024 | Besremi |
| Gilead Sciences, INC. | $28.90 | 2025 | Trodelvy |
| Genzyme Corporation | $27.94 | 2025 | |
| Adc Therapeutics America, INC. | $26.29 | 2025 | |
| Tersera Therapeutics LLC | $24.14 | 2025 | Zoladex |
| Spectrum Pharmaceuticals INC. | $22.70 | 2025 | Rolvedon |
| Regeneron Healthcare Solutions, INC. | $21.59 | 2024 | Libtayo |
| Stemline Therapeutics INC. | $21.24 | 2025 | Orserdu |
| Glaxosmithkline, LLC. | $20.25 | 2024 | Ojjaara |
| Verastem, INC. | $19.76 | 2025 | Avmapki Fakzynja Co-Pack |
| Beone Medicines USA, INC. | $17.43 | 2025 | Brukinsa |
| Sobi, INC | $14.68 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Duffy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.